Company intelligence / Profile preview

Cynapsus Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Cynapsus Therapeutics was a specialty pharmaceutical company focused on the development of a sublingual thin-film formulation of apomorphine for the treatment of "off" episodes in Parkinson's disease. The company's lead candidate, APL-130277, was designed to provide a fast-acting, easy-to-administer alternative to traditional injectable apomorphine. In 2016, the company was acquired by Sunovion Pharmaceuticals for approximately $624 million. The lead product was eventually approved by the FDA in 2020 and is marketed under the brand name Kynmobi.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

MonoSol Rx

Beyond the preview

Go deeper on Cynapsus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cynapsus Therapeutics.

Explore the full profile